Nautilus Biotechnology Q3 2025 net loss $13.6M; operating expenses down 19% to $15.5M

Nautilus Biotechnology, Inc.

2025-Q3 EPS reported -$0.36

Net loss of $13.6M for Q3 2025, improved from $16.4M loss in Q3 2024.
Operating expenses $15.5M, down 19% from $19.1M year-over-year.
Cash and investments $168.5M as of Sept 30, 2025.
Progress on Tau proteoform samples; early access program expected H1 2026; commercial launch late 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.